These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10720724)

  • 1. Toxicity of drug abuse--amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use.
    Mørland J
    Toxicol Lett; 2000 Mar; 112-113():147-52. PubMed ID: 10720724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion].
    Molero-Chamizo A
    Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute and long-term effects of ecstasy].
    Salzmann J; Marie-Claire C; Noble F
    Presse Med; 2004 Oct; 33(18 Suppl):24-32. PubMed ID: 15617173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.
    Thomasius R; Petersen K; Buchert R; Andresen B; Zapletalova P; Wartberg L; Nebeling B; Schmoldt A
    Psychopharmacology (Berl); 2003 Apr; 167(1):85-96. PubMed ID: 12632248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDMA: interactions with other psychoactive drugs.
    Mohamed WM; Ben Hamida S; Cassel JC; de Vasconcelos AP; Jones BC
    Pharmacol Biochem Behav; 2011 Oct; 99(4):759-74. PubMed ID: 21756931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide.
    Freezer A; Salem A; Irvine RJ
    Brain Res; 2005 Apr; 1041(1):48-55. PubMed ID: 15804499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How MDMA's pharmacology and pharmacokinetics drive desired effects and harms.
    Michael White C
    J Clin Pharmacol; 2014 Mar; 54(3):245-52. PubMed ID: 24431106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key interindividual determinants in MDMA pharmacodynamics.
    Papaseit E; Torrens M; Pérez-Mañá C; Muga R; Farré M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):183-195. PubMed ID: 29303006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').
    McCann UD; Slate SO; Ricaurte GA
    Drug Saf; 1996 Aug; 15(2):107-15. PubMed ID: 8884162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users.
    Morefield KM; Keane M; Felgate P; White JM; Irvine RJ
    Addiction; 2011 Jul; 106(7):1293-300. PubMed ID: 21320226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ecstasy: psychostimulant, hallucinogen and toxic substance].
    Burnat P; Le Brumant-Payen C; Huart B; Ceppa F; Pailler FM
    Presse Med; 1996 Sep; 25(26):1208-12. PubMed ID: 8949626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Death following ingestion of MDMA (ecstasy) and moclobemide.
    Vuori E; Henry JA; Ojanperä I; Nieminen R; Savolainen T; Wahlsten P; Jäntti M
    Addiction; 2003 Mar; 98(3):365-8. PubMed ID: 12603236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Psychiatric and cognitive long-term effects of ecstasy].
    Høiseth G; Løvåsdal Ø; Titze TK; Bramness JG; Bachs L
    Tidsskr Nor Laegeforen; 2006 Feb; 126(5):596-8. PubMed ID: 16505868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).
    Pardo-Lozano R; Farré M; Yubero-Lahoz S; O'Mathúna B; Torrens M; Mustata C; Pérez-Mañá C; Langohr K; Cuyàs E; Carbó Ml; de la Torre R
    PLoS One; 2012; 7(10):e47599. PubMed ID: 23112822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of MDMA (ecstasy) use and neurotoxicity.
    Franken IH
    Eur Psychiatry; 2001 Dec; 16(8):508-9. PubMed ID: 11777745
    [No Abstract]   [Full Text] [Related]  

  • 16. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor.
    Hanson KL; Luciana M
    J Clin Exp Neuropsychol; 2010 Apr; 32(4):337-49. PubMed ID: 20397296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users.
    Verheyden SL; Henry JA; Curran HV
    Hum Psychopharmacol; 2003 Oct; 18(7):507-17. PubMed ID: 14533132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuropsychiatric disorders induced by MDMA ("Ecstasy")].
    Bailly D
    Encephale; 1999; 25(6):595-602. PubMed ID: 10668603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of MDMA and methylphenidate on social cognition.
    Schmid Y; Hysek CM; Simmler LD; Crockett MJ; Quednow BB; Liechti ME
    J Psychopharmacol; 2014 Sep; 28(9):847-56. PubMed ID: 25052243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxicity of MDMA: Main effects and mechanisms.
    Costa G; Gołembiowska K
    Exp Neurol; 2022 Jan; 347():113894. PubMed ID: 34655576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.